These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 30293754)
1. Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP). Gaudio F; Mazza P; Carella AM; Mele A; Palazzo G; Pisapia G; Carluccio P; Pastore D; Cascavilla N; Specchia G; Pavone V Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):35-40. PubMed ID: 30293754 [TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients. Gaudio F; Mazza P; Mele A; Palazzo G; Carella AM; Delia M; Pisapia G; Pastore D; Cascavilla N; Pavone V; Specchia G Ann Hematol; 2019 Jun; 98(6):1449-1455. PubMed ID: 30868307 [TBL] [Abstract][Full Text] [Related]
3. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience. Mediwake H; Morris K; Curley C; Butler J; Kennedy G Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950 [TBL] [Abstract][Full Text] [Related]
4. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center. Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892 [No Abstract] [Full Text] [Related]
5. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP). Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707 [TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Peggs KS; Blaise D; Afanasyev B; Diez-Martin JL; Sierra J; Bloor A; Martinez C; Robinson S; Malladi R; El-Cheikh J; Corradini P; Montoto S; Dreger P; Sureda A Br J Haematol; 2018 Apr; 181(1):86-96. PubMed ID: 29468647 [TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099 [TBL] [Abstract][Full Text] [Related]
9. Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. Jeong SH; Song HN; Park JS; Yang DH; Koh Y; Yoon SS; Lee HW; Eom HS; Won JH; Kim WS; Kim SJ Biol Blood Marrow Transplant; 2018 Dec; 24(12):2471-2478. PubMed ID: 30064012 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N; Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686 [TBL] [Abstract][Full Text] [Related]
11. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Genadieva-Stavrik S; Boumendil A; Dreger P; Peggs K; Briones J; Corradini P; Bacigalupo A; Socié G; Bonifazi F; Finel H; Velardi A; Potter M; Bruno B; Castagna L; Malladi R; Russell N; Sureda A Ann Oncol; 2016 Dec; 27(12):2251-2257. PubMed ID: 28007754 [TBL] [Abstract][Full Text] [Related]
12. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant. Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748 [TBL] [Abstract][Full Text] [Related]
13. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794 [TBL] [Abstract][Full Text] [Related]
14. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant. Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455 [TBL] [Abstract][Full Text] [Related]
15. Human Leukocyte Antigen-Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Analysis. Lacerda MP; Arrais Rodrigues C; Pereira AD; Novis Y; Fonseca M; Silva RL; Macedo MCMA; Hamerschlak N; Esteves I; Schmidt Filho J; Nascimento MM; Rocha V Biol Blood Marrow Transplant; 2017 Apr; 23(4):705-707. PubMed ID: 28108270 [TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Blaise D; Peggs KS; Afanasyev B; Diez-Martin JL; Corradini P; Michonneau D; Robinson S; Gutiérrez García G; Bonifazi F; Yakoub-Agha I; Gülbas Z; Bloor A; Delage J; Esquirol A; Malladi R; Scheid C; El-Cheikh J; Ghesquières H; Montoto S; Dreger P; Sureda A Cancer; 2019 Jan; 125(1):90-98. PubMed ID: 30351488 [TBL] [Abstract][Full Text] [Related]
17. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma. Akhtar S; Rauf SM; Elhassan TA; Maghfoor I Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363 [TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas. Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369 [TBL] [Abstract][Full Text] [Related]
19. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Devetten MP; Hari PN; Carreras J; Logan BR; van Besien K; Bredeson CN; Freytes CO; Gale RP; Gibson J; Giralt SA; Goldstein SC; Gupta V; Marks DI; Maziarz RT; Vose JM; Lazarus HM; Anderlini P Biol Blood Marrow Transplant; 2009 Jan; 15(1):109-17. PubMed ID: 19135949 [TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. Todisco E; Castagna L; Sarina B; Mazza R; Anastasia A; Balzarotti M; Banna G; Tirelli U; Soligo D; Santoro A Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]